Posts by: Marta Figueiredo

Marta Figueiredo

Marta Figueiredo holds a BSc in Biology and a MSc in Evolutionary and Developmental Biology from the University of Lisbon, Portugal. She is currently finishing her PhD in Biomedical Sciences at the University of Lisbon, where she focused her research on the role of several signalling pathways in thymus and parathyroid glands embryonic development.

March 23, 2020March 23, 2020

Better Responses with IO102-Keytruda Combo Likely in Ongoing NSCLC Trial

News

Adding IO Biotech’s lead candidate, IO102, to first-line treatment with Keytruda (pembrolizumab) is likely to result in better response rates in people with metastatic non-small cell lung cancer (NSCLC), an interim analysis ... Read more

March 20, 2020March 20, 2020

Harbour BioMed Gets FDA Nod to Start US Trials of 2 Immunotherapies

News

The U.S. Food and Drug Administration (FDA) has approved Harbour BioMed’s investigational new drug applications to initiate U.S. clinical trials testing two of its immunotherapy candidates — HBM9167 and HBM4003 — in ... Read more

March 6, 2020March 6, 2020

Cabiralizumab Plus Opdivo Failed to Halt Progression of Advanced Pancreatic Cancer, Trial Shows

News

Combining Five Prime Therapeutics‘ investigational therapy cabiralizumab with Opdivo (nivolumab) — with and without chemotherapy — failed to halt disease progression in people with advanced pancreatic cancer, compared with standard ... Read more

December 13, 2019

Bemcentinib-Keytruda Combo Effective in Some Advanced NSCLC Patients with Poor Prognosis

News

Combining bemcentinib with Keytruda (pembrolizumab) is effective and delays disease progression in people with previously treated advanced non-small cell lung cancer (NSCLC), particularly in those with AXL-positive tumors. Those updated results from a Phase 2 clinical ... Read more

November 11, 2019

2 Imfinzi Combos Delay Cancer Progression in Metastatic NSCLC, Interim Phase 3 Data Show

News

Adding Imfinzi (durvalumab) — alone or in combination with tremelimumab — to standard first-line chemotherapy significantly delayed disease progression or death in people with metastatic non-small cell lung cancer (NSCLC), compared with ... Read more

October 9, 2019October 9, 2019

Keytruda Approved in China as First-Line Lung Cancer Treatment

News

The Chinese National Medical Products Administration (NMPA) has approved Keytruda (pembrolizumab) as a first-line treatment for locally advanced or metastatic non-small cell lung cancer (NSCLC), Merck (known as MSD outside the U.S. and Canada) announced. ... Read more

October 8, 2019

Opdivo-Yervoy Combo Prolongs Survival in Patients with Advanced NSCLC, Phase 3 Study Shows

News

A combination of Opdivo (nivolumab) and low-dose Yervoy (ipilimumab) induces significant survival benefits in people with advanced non-small cell lung cancer (NSCLC), compared to chemotherapy alone, data from a Phase ... Read more

August 27, 2019September 18, 2019

EU Committee Recommends Orphan Drug Status for Ziopharm’s IL-12 Gene Therapy for Glioblastoma

News

A European Medicines Agency (EMA) committee has recommended orphan drug designation for Ziopharm Oncology‘s interleukin (IL)-12 gene therapy — known as the Controlled IL-12 platform — for the treatment of glioblastoma, a ... Read more

October 31, 2018October 31, 2018

Immunotherapy Particularly Effective Against Aggressive Hereditary Melanoma, Study Reports

News

Patients with hereditary melanoma associated with mutations in the CDKN2A gene respond well to immunotherapy, possible due to an increased mutational load in these tumors, a study suggests. The study, ... Read more

October 24, 2018

Keytruda Improves Survival in Patients with Relapsed or Metastatic Head, Neck Cancer, Interim Data Show

News

First-line treatment with Keytruda (pembrolizumab) — alone or in combination with standard chemotherapy — significantly prolongs survival of patients with recurrent or metastatic head and neck squamous cell carcinoma (HNSCC), compared ... Read more